产品名称
OV56, NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA, 96020759, human ovary, Epithelial
biological source
human ovary
packaging
tube of 5 μg 96020759-DNA-5UG
pkg of vial of cells 96020759-1VL
growth mode
Adherent
karyotype
Not specified
morphology
Epithelial
products
VEGF
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−196°C
Biochem/physiol Actions
Human ovarian serous carcinoma (ascites) stage IV, poorly differentiated
STR-PCR Data: Amelogenin: X
CSF1PO: 11
D13S317: 8,9
D16S539: 10,13
D5S818: 11,12
D7S820: 10
THO1: 6,9
TPOX: 9,11
vWA: 15,19
CSF1PO: 11
D13S317: 8,9
D16S539: 10,13
D5S818: 11,12
D7S820: 10
THO1: 6,9
TPOX: 9,11
vWA: 15,19
The OV56 cell line was established from ascitic fluid derived from a 46-year-old female patient diagnosed with ovarian cancer. The tumour was characterised as stage IV, poorly differentiated. Immunocytochemical staining of the cells was reported to show strong staining for cytokeratin (CK), weak staining for carcinoembryonic antigen (CEA) and strong staining for human milk fat globulin (HMFG-2). Production of vascular endothelial growth factor (VEGF) has been detected by ELISA. The patient had received sequential treatment with cisplatin and cyclophosphamide, cisplatin and etoposide and subsequently tamoxifen.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Preparation Note
DMEM:HAMS F12 (1:1) + 2mM Glutamine + 5% Foetal Bovine Serum (FBS) + 0.5 ug/ml hydrocortisone + 10ug/ml insulin
Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm2 using 0.25% trypsin/EDTA; 5% CO2; 37°C.
法规信息
高风险级别生物产品--人源产品
动植物来源培养基
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持